Neuphoria Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEUP research report →
Range $7 – $7
Price Chart
About the company
Neuphoria Therapeutics Inc. , a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
- CEO
- Spyridon Papapetropoulos
- IPO
- 2021
- Employees
- 1
- HQ
- Millis, MA, US
Get TickerSpark's AI analysis on NEUP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.72M
- P/E
- -2.72
- PEG
- 0.01
- P/S
- 10.69
- P/B
- 0.53
- EV/EBITDA
- 0.96
- Div Yield
- 0.00%
- Gross Margin
- 43.55%
- Op Margin
- -637.84%
- Net Margin
- -423.32%
- ROE
- -18.55%
- ROIC
- -27.96%
Latest fiscal year · YoY change
- Revenue
- $1.17M-92.5%
- Gross Profit
- $511.21K-96.6%
- Op Income
- $-9,810,480
- Net Income
- $-13,451,931-3539.3%
- EPS
- $-3.06-1230.4%
- OCF Growth
- -116.0%
- FCF Growth
- -116.0%
- 52W High
- $5.53
- 52W Low
- $2.26
- 50D MA
- $3.23
- 200D MA
- $4.06
- Beta
- 0.77
- RSI (14)
- 19
- Avg Volume
- 26.53K
No earnings-call transcripts are available for NEUP yet.
- Free Float
- 77.5%
- Shares Outstanding
- 5.41M
- Float Shares
- 4.19M
of shares held by institutions
22 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Lynx1 Capital Management LP | 875.33K | 0 |
| Advisorshares Investments LLC | 312.89K | ▲ 59.99K |
| Vanguard Capital Management LLC | 173.49K | 0 |
| Balyasny Asset Management L.P. | 142.23K | ▲ 45 |
| Shay Capital LLC | 130.02K | ▼ 25.80K |
| Geode Capital Management, LLC | 50.64K | ▲ 1.12K |
| Ikarian Capital, LLC | 47.44K | 0 |
| Citadel Advisors LLC | 44.05K | ▼ 28.51K |
| Vanguard Fiduciary Trust Co | 33.81K | 0 |
| Adar1 Capital Management, LLC | 30.00K | 0 |
| Vanguard Group Inc | 20.95K | 0 |
| Jane Street Group, LLC | 18.17K | ▲ 3.27K |
Held by 21 ETFs
Biggest fund positions in NEUP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 20, 26 | Wilson David Ian | other | 8,537 |
| Jan 20, 26 | Davies Peter Miles Winston | other | 8,537 |
| Jan 20, 26 | Fisher Alan | other | 17,073 |
| Jan 20, 26 | Ryan Jane | other | 8,537 |
| Oct 21, 25 | Lynx1 Capital Management LP | buy | 639,110 |
| Oct 21, 25 | Lynx1 Capital Management LP | other | 0 |
| Aug 27, 25 | Papapetropoulos Spyros | other | 34,559 |
| Apr 16, 25 | Papapetropoulos Spyros | other | 27,000 |
| Apr 16, 25 | Papapetropoulos Spyros | other | 270,000 |
| Apr 16, 25 | Davies Peter Miles Winston | other | 6,783 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NEUP coverage
Recent articles, reports, and earnings notes.
No research on NEUP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NEUP report →Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?
prnewswire.com · Aug 4
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAX
globenewswire.com · Jul 30
Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders?
prnewswire.com · Jul 29
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLC
globenewswire.com · Jul 28
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders
gurufocus.com · Jul 24
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)
gurufocus.com · Jul 24
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders
businesswire.com · Jul 24
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)
prnewswire.com · Jul 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.